IN2014DN08632A - - Google Patents

Info

Publication number
IN2014DN08632A
IN2014DN08632A IN8632DEN2014A IN2014DN08632A IN 2014DN08632 A IN2014DN08632 A IN 2014DN08632A IN 8632DEN2014 A IN8632DEN2014 A IN 8632DEN2014A IN 2014DN08632 A IN2014DN08632 A IN 2014DN08632A
Authority
IN
India
Prior art keywords
production
during
eye drop
chelating agent
diquafosol
Prior art date
Application number
Other languages
English (en)
Inventor
Akiko Sakatani
Tatsuo Ikei
Koji Inagaki
Masatsugu Nakamura
Kazuhiro Hosoi
Mikiko Saito
Masaki Sonoda
Yoko Fukui
Mitsuaki Kuwano
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49259901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN08632(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of IN2014DN08632A publication Critical patent/IN2014DN08632A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN8632DEN2014 2012-03-26 2013-03-25 IN2014DN08632A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012069157 2012-03-26
PCT/JP2013/058519 WO2013146649A1 (fr) 2012-03-26 2013-03-25 Gouttes oculaires contenant du diquafosol

Publications (1)

Publication Number Publication Date
IN2014DN08632A true IN2014DN08632A (fr) 2015-05-22

Family

ID=49259901

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8632DEN2014 IN2014DN08632A (fr) 2012-03-26 2013-03-25

Country Status (26)

Country Link
US (4) US9486529B2 (fr)
EP (2) EP3431092A1 (fr)
JP (6) JP5625081B2 (fr)
KR (5) KR101935484B1 (fr)
CN (2) CN104203254A (fr)
AU (3) AU2013241507A1 (fr)
BR (1) BR112014023402B1 (fr)
CA (1) CA2868390C (fr)
DK (1) DK2832359T3 (fr)
EA (1) EA028848B1 (fr)
ES (1) ES2702575T3 (fr)
GE (1) GEP20166470B (fr)
HK (2) HK1204922A1 (fr)
HU (1) HUE041671T2 (fr)
IN (1) IN2014DN08632A (fr)
MX (1) MX353874B (fr)
MY (1) MY169816A (fr)
NZ (1) NZ631041A (fr)
PH (1) PH12014501955A1 (fr)
PL (1) PL2832359T3 (fr)
PT (1) PT2832359T (fr)
SG (2) SG11201405799TA (fr)
TR (1) TR201820073T4 (fr)
TW (4) TWI625135B (fr)
UA (1) UA113981C2 (fr)
WO (1) WO2013146649A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431092A1 (fr) * 2012-03-26 2019-01-23 Santen Pharmaceutical Co., Ltd. Solution ophtalmique comprenant du diquafosol
KR102281620B1 (ko) 2014-01-10 2021-07-23 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 함유하는 의약 조성물
BR112017013841A2 (pt) * 2014-12-25 2018-06-19 Santen Pharmaceutical Co., Ltd. solução oftálmica aquosa
RU2742032C2 (ru) * 2015-06-05 2021-02-01 Сантен Фармасьютикал Ко., Лтд. Терапевтическое средство против сухости глаз, характеризуемое нанесением на глаза пациентов с сухостью глаз, носящих гибкие контактные линзы
TWI711453B (zh) * 2015-06-05 2020-12-01 日商參天製藥股份有限公司 抑制水性點眼液中之洛赫西定類的殘存率降低之方法
CN107709345A (zh) * 2015-06-29 2018-02-16 雅玛山酱油株式会社 P1，p4‑二(尿苷5′）‑四磷酸晶体的保存方法
JP6688057B2 (ja) * 2015-12-01 2020-04-28 日水製薬株式会社 グラム染色用後染色試液及びグラム染色方法
CN117137866A (zh) * 2018-02-28 2023-12-01 参天制药株式会社 含有地夸磷索及阳离子性聚合物的眼科用组合物
CN108403625A (zh) * 2018-04-11 2018-08-17 东莞解石医药科技有限公司 一种含有螯合剂的地夸磷索四钠滴眼液
KR102656181B1 (ko) * 2019-08-27 2024-04-08 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
CN113720924A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种地夸磷索四钠的含量及有关物质检测方法
JPWO2022107790A1 (fr) * 2020-11-18 2022-05-27
WO2022107791A1 (fr) * 2020-11-18 2022-05-27 参天製薬株式会社 Solution ophtalmique aqueuse contenant un polyhexaméthylène biguanide ou un sel de celui-ci
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
CN112933040A (zh) * 2021-02-04 2021-06-11 合肥博思科创医药科技有限公司 一种舒更葡糖钠注射液的制备方法
WO2023195718A1 (fr) * 2022-04-04 2023-10-12 서울대학교산학협력단 Composition permettant de supprimer la sucrosité et procédé de suppression de sucrosité d'aliments
CN117838628B (zh) * 2024-03-01 2024-05-28 广州市桐晖药业有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH075456B2 (ja) * 1988-10-01 1995-01-25 参天製薬株式会社 点眼液
JP2530491B2 (ja) 1988-12-20 1996-09-04 参天製薬株式会社 ヒアルロン酸点眼液
TW200402B (fr) 1990-08-13 1993-02-21 Senju Pharma Co
US5504113A (en) 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
AU738907C (en) 1997-02-06 2002-05-16 Merck Sharp & Dohme Corp. Dinucleotides and their use
NZ501696A (en) 1997-07-25 2001-08-31 Inspire Pharmaceuticals Inc Method for large-scale production of sodium and ammonium salts of di(uridine 5')-tetraphosphate
KR19990074047A (ko) 1998-03-03 1999-10-05 김수복 콘택트렌즈용 세척, 소독 및 보존제 조성물
KR100595956B1 (ko) 1998-08-21 2006-07-03 센주 세이야꾸 가부시키가이샤 수성액 제약학적 조성물
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
WO2001091795A1 (fr) 2000-05-30 2001-12-06 Santen Pharmaceutical Co., Ltd. Promoteurs de l'extension de l'epithelium corneen
JP4003008B2 (ja) * 2000-05-30 2007-11-07 参天製薬株式会社 角膜上皮伸展促進剤
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US6583181B1 (en) 2000-11-22 2003-06-24 Lonza Inc. Antimicrobial quaternary ammonium compositions with reduced ocular irritation
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
JP2003160491A (ja) * 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液
US20030109488A1 (en) 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
PL1468697T3 (pl) 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań
JP4806956B2 (ja) 2004-04-20 2011-11-02 大正製薬株式会社 点眼用液剤
US20060073172A1 (en) 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
RS51506B (en) 2004-12-02 2011-06-30 Venus Remedies Limited H. O&R&D. BETA-LACTAMASE INTERFERENCE MIXTURES OF MEDIUM RESISTANCE TO ANTIBIOTICS USING BETA-LACTAMASE INHIBITORS USED FOR INJECTION
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
JP4168071B2 (ja) 2005-12-08 2008-10-22 興和株式会社 点眼用組成物
JP2008247828A (ja) 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
JP2009040727A (ja) * 2007-08-09 2009-02-26 Towa Yakuhin Kk ラタノプロストを有効成分とする安定な点眼液剤
CN100534423C (zh) * 2007-11-30 2009-09-02 张咏梅 一种保质期长的氯霉素滴眼液及其制备方法
US8119112B2 (en) 2008-01-31 2012-02-21 Bausch & Lomb Incorporated Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid
CN101461778A (zh) * 2009-01-06 2009-06-24 河北科技大学 不含抑菌剂的盐酸环丙沙星滴眼液及其制备方法
WO2010085572A1 (fr) * 2009-01-23 2010-07-29 Inspire Pharmaceuticals, Inc. Méthode de traitement du syndrome de l'œil sec par l'azithromycine
CN102100693A (zh) * 2009-12-16 2011-06-22 沈阳兴齐制药有限公司 一种含有肌肽的人工泪液及其制备方法
KR20110104367A (ko) 2010-03-16 2011-09-22 삼천당제약주식회사 무보존제 안과용 조성물
AU2011281035B2 (en) 2010-07-21 2014-10-02 Cumberland Pharmaceuticals, Inc. Acetycysteine compositions and methods of use thereof
AU2011299851A1 (en) 2010-09-10 2013-04-04 Santen Pharmaceutical Co., Ltd. Agent for treatment of dry eye characterized by combining P2Y2 receptor agonist with hyaluronic acid or salt thereof, method for treating dry eye, and use of the P2Y2 receptor agonist and hyaluronic acid or salt thereof
EA027736B1 (ru) 2010-12-28 2017-08-31 Сантен Фармасьютикал Ко., Лтд. Глазной раствор, содержащий диквафозол, способ его получения и способ ингибирования образования нерастворимого осадка
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
MY185108A (en) 2012-03-26 2021-04-30 Dilafor Ab Method for treatment of labor arrest
EP3431092A1 (fr) 2012-03-26 2019-01-23 Santen Pharmaceutical Co., Ltd. Solution ophtalmique comprenant du diquafosol

Also Published As

Publication number Publication date
JP6389544B2 (ja) 2018-09-12
JP2019070053A (ja) 2019-05-09
US20150072951A1 (en) 2015-03-12
AU2016201110A1 (en) 2016-03-10
TR201820073T4 (tr) 2019-01-21
AU2013241507A1 (en) 2014-10-09
JP7042762B2 (ja) 2022-03-28
US10632139B2 (en) 2020-04-28
JP2013227291A (ja) 2013-11-07
TW202015704A (zh) 2020-05-01
WO2013146649A1 (fr) 2013-10-03
KR101536885B1 (ko) 2015-07-14
TW202041220A (zh) 2020-11-16
JP2018076384A (ja) 2018-05-17
SG10201607872PA (en) 2016-11-29
TWI625135B (zh) 2018-06-01
JP6126041B2 (ja) 2017-05-10
US9486529B2 (en) 2016-11-08
CN113018259A (zh) 2021-06-25
NZ631041A (en) 2016-10-28
AU2016201110B2 (en) 2017-06-15
PH12014501955B1 (en) 2014-11-17
MX2014011468A (es) 2015-01-12
TW201343196A (zh) 2013-11-01
TW201806583A (zh) 2018-03-01
GEP20166470B (en) 2016-04-25
AU2016201111A1 (en) 2016-03-10
JP2014132039A (ja) 2014-07-17
HK1206648A1 (en) 2016-01-15
DK2832359T3 (en) 2019-02-04
KR20180079469A (ko) 2018-07-10
EP2832359B1 (fr) 2018-11-14
MX353874B (es) 2018-02-01
US20200215093A1 (en) 2020-07-09
KR20190002751A (ko) 2019-01-08
CA2868390A1 (fr) 2013-10-03
PH12014501955A1 (en) 2014-11-17
US20180353531A1 (en) 2018-12-13
JP5625081B2 (ja) 2014-11-12
KR101935484B1 (ko) 2019-01-04
CA2868390C (fr) 2020-03-31
TWI723722B (zh) 2021-04-01
HK1204922A1 (en) 2015-12-11
JP2017119718A (ja) 2017-07-06
PL2832359T3 (pl) 2019-04-30
KR20140136980A (ko) 2014-12-01
PT2832359T (pt) 2019-01-29
EP3431092A1 (fr) 2019-01-23
HUE041671T2 (hu) 2019-05-28
MY169816A (en) 2019-05-16
EA028848B1 (ru) 2018-01-31
TWI692364B (zh) 2020-05-01
EP2832359A1 (fr) 2015-02-04
JP2022075813A (ja) 2022-05-18
KR101875845B1 (ko) 2018-07-06
SG11201405799TA (en) 2014-11-27
US10071113B2 (en) 2018-09-11
US20170020910A1 (en) 2017-01-26
TWI757799B (zh) 2022-03-11
KR20200096708A (ko) 2020-08-12
JP7447176B2 (ja) 2024-03-11
EP2832359A4 (fr) 2015-03-25
JP6483299B2 (ja) 2019-03-13
BR112014023402B1 (pt) 2020-09-29
CN104203254A (zh) 2014-12-10
KR20150027312A (ko) 2015-03-11
EA201491771A1 (ru) 2015-01-30
ES2702575T3 (es) 2019-03-04
UA113981C2 (xx) 2017-04-10
US11166974B2 (en) 2021-11-09

Similar Documents

Publication Publication Date Title
IN2014DN08632A (fr)
PH12015500115B1 (en) Glucagon analogues
IN2015DN01156A (fr)
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2014113429A3 (fr) Composés de type pyrrolopyrimidine substituée, compositions en contenant et méthodes de traitement faisant appel à eux
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
IN2012DN03312A (fr)
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
WO2014164285A3 (fr) Utilisation de lévocétirizine et de montelukast dans le traitement de la vascularite
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MY161032A (en) Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
MX2014005405A (es) Una composicion de limpieza personal.
EA201492081A1 (ru) (r)-нифурател, его применение в лечении инфекций и синтез (r)- и (s)-нифуратела
MX2017015293A (es) Composicion para tratar lesiones tisulares.
MY182591A (en) Compositions for use in treating eye disorders using dipyridamole
NZ707081A (en) Agent for preventing or improving decline in brain function
EA033769B9 (ru) Отселектированный амид -гидроксимасляной кислоты и его применения при лечении злоупотребления алкоголем
HK1198632A1 (en) Compositions comprising cimetidine and n,o-carboxymethyl chitosan for the prevention and therapy of pathologies of the skin and the mucous membranes and in the odontostomatological field no-
EP2886112A4 (fr) Composition contenant comme principe actif de la s-allyl-l-cystéine et destinée à prévenir ou à traiter des maladies oculaires, et formulation pharmaceutique contenant cette composition
PH12015500070A1 (en) Pediatric oral liquid compositions containing nepadutant
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
TH157373A (th) สารละลายที่เกี่ยวกับตาที่ประกอบรวมด้วยไดควาโฟซอล
TN2010000232A1 (en) Formulations for cancer treatment